UK markets open in 3 hours 10 minutes
  • NIKKEI 225

    29,315.17
    -853.10 (-2.83%)
     
  • HANG SENG

    29,342.49
    -731.68 (-2.43%)
     
  • CRUDE OIL

    63.06
    -0.47 (-0.74%)
     
  • GOLD FUTURES

    1,766.00
    -9.40 (-0.53%)
     
  • DOW

    31,402.01
    -559.85 (-1.75%)
     
  • BTC-GBP

    33,809.68
    -2,481.08 (-6.84%)
     
  • CMC Crypto 200

    942.33
    -52.33 (-5.26%)
     
  • ^IXIC

    13,119.43
    -478.54 (-3.52%)
     
  • ^FTAS

    3,788.74
    -6.32 (-0.17%)
     

AZN EQUITY ALERT: Labaton Sucharow Announces Filing of Securities Class Action Lawsuit Against AstraZeneca PLC – NASDAQ: AZN

·2-min read

Labaton Sucharow, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for AstraZeneca investors under the federal securities laws.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) initial clinical trials for AZD1222, the Company’s coronavirus vaccine hopeful, had suffered from a critical manufacturing error, resulting in a substantial number of trial participants receiving half the designed dosage; (2) clinical trials for AZD1222 consisted of a patchwork of disparate patient subgroups, each with subtly different treatments, undermining the validity and import of the conclusions that could be drawn from the clinical data across these disparate patient populations; (3) certain clinical trial participants for AZD1222 had not received a second dose at the designated time points, but rather received the second dose up to several weeks after the dose had been scheduled to be delivered according to the original trial design; (4) AstraZeneca had failed to include a substantial number of patients over 55 years of age in its clinical trials for AZD1222, despite this patient population being particularly vulnerable to the effects of COVID-19 and thus a high priority target market for the drug; (5) AstraZeneca’s clinical trials for AZD1222 had been hamstrung by widespread flaws in design, errors in execution, and a failure to properly coordinate and communicate with regulatory authorities and the general public; (6) as a result of the foregoing, the clinical trials for AZD1222 had not been conducted in accordance with industry best practices and acceptable standards and the data and conclusions that could be derived from the clinical trials was of limited utility; and (7) as a result of the foregoing, AZD1222 was unlikely to be approved for commercial use in the United States in the short term, one of the largest potential markets for the drug.

If you currently own shares of AstraZeneca and want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll-free number (800) 321-0476 or via email at dschwartz@labaton.com

About the Firm

Labaton Sucharow LLP is one of the world’s leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at http://www.labaton.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005718/en/

Contacts

David J. Schwartz
(800) 321-0476
dschwartz@labaton.com